A Chinese medicine composition and its application in preparing medicine for treating atrial fibrillation

Abstract

The present invention discloses a Chinese medicine composition and its application in preparing a drug for treating atrial fibrillation. The raw materials of the Chinese medicine composition include: ginseng, ganoderma lucidum, safflower, musk, bezoar, bear gall, pearl, toad venom, aconite and borneol. The Chinese medicine composition has a good therapeutic effect on atrial fibrillation. A large amount of experimental data proves that the Chinese medicine composition can effectively reduce the incidence of atrial fibrillation, the duration of atrial fibrillation and the duration of P wave through the reasonable compatibility of various components, relieve the symptoms of atrial fibrillation from multiple aspects, and block the progression of the disease. The prescription is safe and reliable, and has no toxic side effects on the human body.

Description

Technical Field

[0001] The present invention relates to the field of medical technology, and in particular to a Chinese medicine composition and application thereof in preparing a medicine for treating atrial fibrillation. Background Art

[0002] A large-scale epidemiological survey in my country showed that the prevalence of atrial fibrillation (AF) in the population aged 35 to 85 was 0.61% in 2003, and 0.71% in the population aged 35 and above in 2012-2015. The prevalence of AF in the population aged 45 and above was 1.8% in 2014-2016 (1.9% and 1.7% in men and women, respectively). The prevalence of AF increases with age. Among the population aged 75 and above, the prevalence was 5.4% and 4.9% in men and women, respectively. Based on this study from 2014 to 2016, combined with the data of the seventh census in my country in 2020, it is estimated that there are about 12 million patients with AF in my country. Since about one-third of patients are unaware of their AF and some paroxysmal AF are missed, the actual number of patients with AF in my country should be higher than the above estimate. The risk of death in patients with atrial fibrillation is 1.5-1.9 times that of patients without atrial fibrillation. The mechanism may be related to the increased risk of thromboembolism, heart failure, and the synergistic effect of comorbid diseases.

[0003] Atrial fibrillation is a common clinical rapid arrhythmia, which belongs to the category of "palpitations" and "flustered palpitations" in traditional Chinese medicine. Symptoms such as palpitations, dizziness, and fatigue are common during attacks. Due to the accelerated pace of modern life and the increased intensity of mental work, mental-related diseases are becoming more and more common, such as sleep disorders, anxiety, and depression. Emotional disorders, excessive worry, tediousness, and lack of inner concentration; phlegm and dampness, blood stasis, such as atherosclerosis, block the blood vessels, and the mind loses its nourishment, or real evil directly disturbs the mind, which can all cause anxiety, insomnia, and mental disorders. Mental diseases lead to abnormal control and regulation functions, and cardiac rhythm and frequency disorders, resulting in palpitations (atrial fibrillation arrhythmia). The disordered heartbeat, pulse disorder, and abnormal blood circulation during atrial fibrillation will lead to the endogenous generation of phlegm and blood stasis, poor blood circulation, and lack of nourishment for the mind, thereby aggravating the pulse and mental disorders and forming a vicious circle.

[0004] Providing a drug to treat atrial fibrillation is of great significance. Summary of the invention

[0005] The present invention aims to solve at least one of the above-mentioned technical problems existing in the prior art. To this end, the present invention aims to provide a Chinese medicine composition and its use in preparing a drug for treating atrial fibrillation.

[0006] In order to achieve the above object, the present invention provides the following technical solutions.

[0007] The first aspect of the present invention provides a traditional Chinese medicine composition. The raw medicinal materials of the traditional Chinese medicine composition include, by weight: 380-550 parts of ganoderma lucidum, 150-250 parts of pearls, 5-20 parts of aconite, 150-350 parts of ginseng, 100-200 parts of safflower, 10-50 parts of musk, 5-75 parts of bezoar, 10-80 parts of bear gall, 4-60 parts of toad venom, and 10-20 parts of borneol.

[0008] In some embodiments of the present invention, the raw medicinal materials of the traditional Chinese medicine composition include: 500 parts of Ganoderma lucidum, 250 parts of pearls, 7 parts of aconite, 150 parts of ginseng, 150 parts of safflower, 25 parts of musk, 25 parts of bezoar, 25 parts of bear bile, 25 parts of toad venom, and 15 parts of borneol.

[0009] In some embodiments of the present invention, the raw medicinal materials of the traditional Chinese medicine composition include: 550 parts of Ganoderma lucidum, 250 parts of pearls, 12 parts of aconite, 200 parts of ginseng, 180 parts of safflower, 35 parts of musk, 35 parts of bezoar, 55 parts of bear bile, 45 parts of toad venom, and 15 parts of borneol.

[0010] In some embodiments of the present invention, the raw medicinal materials of the traditional Chinese medicine composition include: 550 parts of Ganoderma lucidum, 200 parts of pearls, 15 parts of aconite, 200 parts of ginseng, 180 parts of safflower, 25 parts of musk, 50 parts of bezoar, 12 parts of bear bile, 45 parts of toad venom, and 10 parts of borneol.

[0011] In some embodiments of the present invention, the raw medicinal materials include any one of dry medicinal materials, fresh medicinal materials, raw medicinal materials, cooked medicinal materials, and processed medicinal materials.

[0012] In some embodiments of the present invention, the raw medicinal material includes any one of a natural medicinal material and an equivalent substitute of a natural medicinal material.

[0013] In some embodiments of the present invention, the traditional Chinese medicine composition further comprises a pharmaceutically acceptable excipient.

[0014] In some embodiments of the present invention, the pharmaceutically acceptable excipients include at least one of a filler, a disintegrant, a diluent, a lubricant, a binder, a wetting agent, a flavoring agent, a suspending agent, a solvent, a sustained-release agent, an emulsifier, an absorption enhancer, a surfactant or a preservative.

[0015] In some embodiments of the present invention, the Chinese medicine composition is a composition formed by mixing the raw medicinal materials of each component after crushing; and / or an extract obtained by mixing the raw medicinal materials of each component, and / or an extract obtained by mixing the raw medicinal materials of each component after separate extraction.

[0016] In some embodiments of the present invention, the dosage form of the Chinese medicine composition includes any one of decoction, tablet, capsule, granule, pill, oral liquid, powder or paste.

[0017] The second aspect of the present invention provides use of the traditional Chinese medicine composition provided in the first aspect in preparing a medicament for treating atrial fibrillation.

[0018] In some embodiments of the present invention, the drug for treating atrial fibrillation comprises at least one of a1)-a3):

[0019] a1) Drugs that reduce the duration of the subject's P wave;

[0020] a2) drugs that reduce the incidence of atrial fibrillation in subjects;

[0021] a3) drugs that reduce the duration of atrial fibrillation in subjects;

[0022] Wherein the subject is a subject suffering from atrial fibrillation.

[0023] The beneficial effects of the present invention are:

[0024] The Chinese medicine composition of the present invention can effectively improve the incidence rate of atrial fibrillation, the duration of atrial fibrillation, and the duration of P waves through the reasonable combination of various components, relieve the symptoms of atrial fibrillation from multiple aspects, and block the progression of the disease. The Chinese medicine composition of the present invention has controllable quality, is convenient for standardized production, has a safe and reliable prescription, and has no toxic side effects on the human body. BRIEF DESCRIPTION OF THE DRAWINGS

[0025] Figure 1 Electrocardiogram test results. DETAILED DESCRIPTION

[0026] The present invention is further described in detail below by specific examples. Unless otherwise specified, the raw materials, reagents or devices used in the examples and comparative examples can be obtained from conventional commercial sources or can be obtained by prior art methods. Unless otherwise specified, the experiments or test methods are conventional methods in the art.

[0027] The first aspect of the present invention provides a traditional Chinese medicine composition. The raw medicinal materials of the traditional Chinese medicine composition include, by weight: 380-550 parts of ganoderma lucidum, 150-250 parts of pearls, 5-20 parts of aconite, 150-350 parts of ginseng, 100-200 parts of safflower, 10-50 parts of musk, 5-75 parts of bezoar, 10-80 parts of bear gall, 4-60 parts of toad venom, and 10-20 parts of borneol.

[0028] Chinese invention patent CN108057066A discloses a pharmaceutical composition for preventing and treating unstable angina pectoris, which is composed of ginseng, aconite, ganoderma lucidum, safflower, artificial musk, bear bile, pearl, toad venom, borneol and bezoar (due to the limited sources of natural bezoar, bezoar is generally cultivated in vitro). The inventors were surprised to find that after greatly adjusting the compatibility combination ratio of the prescription, its original characteristics of invigorating qi and activating blood circulation, warming the meridians and dredging collaterals as the main effects were transformed into invigorating qi and nourishing the heart, calming the mind and settling the mind as the main effects. This transformation has led to the good efficacy of the new prescription for diseases that the original prescription failed to treat, such as atrial fibrillation. The newly formed Chinese medicine composition shows a good therapeutic effect on atrial fibrillation. A large amount of experimental data proves that the new composition can effectively reduce the incidence of atrial fibrillation, the duration of atrial fibrillation, and the duration of P waves through the reasonable compatibility of each component, relieve the symptoms of atrial fibrillation from multiple aspects, and block the progression of the disease. The prescription is safe and reliable, and has no toxic side effects on the human body. The safflower and ginseng in the formula help the ganoderma to replenish qi and nourish the heart, which can greatly replenish the vital energy, restore the pulse and consolidate the body, nourish the heart and nourish the blood, so that the qi is full and the blood is smooth. The calming effect of pearls is exerted when they are combined with ganoderma, which is used in a synergistic way, broadening the scope of pearls to calm the nerves and calm the nerves; pearls are combined with ginseng, a tonic, to improve restlessness and insomnia; they are combined with expectorant drugs such as bezoar to clear away heat and resolve phlegm, calm the wind and stop spasms. Musk and toad venom are pungent, dispersing, warming and unblocking, with aromatic fragrance, opening the orifices and relieving numbness, unblocking the meridians and relieving pain; aconite is pungent, warm and dry, replenishing fire, helping yang, dispersing cold and relieving numbness, which can not only help ganoderma to replenish qi and promote yang, but also prevent the cold nature of bezoar, bear bile and pearls. Bezoar, toad venom, bear bile and borneol are adjuvants, and the four drugs work together to open the orifices, clear the heart, relieve pain and relieve spasms.

[0029] In some embodiments of the present invention, the raw medicinal materials of the traditional Chinese medicine composition include: 500 parts of Ganoderma lucidum, 250 parts of pearls, 7 parts of aconite, 150 parts of ginseng, 150 parts of safflower, 25 parts of musk, 25 parts of bezoar, 25 parts of bear bile, 25 parts of toad venom, and 15 parts of borneol.

[0030] In some embodiments of the present invention, the raw medicinal materials of the traditional Chinese medicine composition include: 550 parts of Ganoderma lucidum, 250 parts of pearls, 12 parts of aconite, 200 parts of ginseng, 180 parts of safflower, 35 parts of musk, 35 parts of bezoar, 55 parts of bear bile, 45 parts of toad venom, and 15 parts of borneol.

[0031] In some embodiments of the present invention, the raw materials for preparing the traditional Chinese medicine composition include: 550 parts of Ganoderma lucidum, 200 parts of pearls, 15 parts of aconite, 200 parts of ginseng, 180 parts of safflower, 25 parts of musk, 50 parts of bezoar, 12 parts of bear bile, 45 parts of toad venom, and 10 parts of borneol.

[0032] In the present invention, weight parts can be any fixed weight expressed in milligrams, grams or kilograms (such as 1 mg, 1 g, 2 g or 1 kg, etc.). For example, a composition consisting of 1 weight part of component a and 9 weight parts of component b can be a composition consisting of 1 gram of component a + 9 grams of component b, or 10 grams of component a + 90 grams of component b, etc. In the composition, the percentage content of a component = (weight parts of the component / sum of weight parts of all components) × 100%. Therefore, in the composition consisting of 1 weight part of component a and 9 weight parts of component b, the content of component a is 10%, and the content of component b is 90%.

[0033] The raw medicinal materials in the present invention refer to the Chinese medicinal materials used as active medicinal materials in the composition of the present invention. The Chinese medicinal materials may include various forms. For example, the Chinese medicinal materials include (but are not limited to) dry medicinal materials, fresh medicinal materials, raw medicinal materials, cooked medicinal materials, processed medicinal materials, or a combination thereof.

[0034] The raw medicinal materials in the present invention can be natural Chinese medicinal materials, or can be equivalent substitutes of natural Chinese medicinal materials. For example, the bezoar can be selected from at least one of natural bezoar, cultured bezoar, in vitro cultured bezoar and artificial bezoar. The musk can be selected from at least one of natural musk and artificial musk.

[0035] In some embodiments of the present invention, the traditional Chinese medicine composition further comprises a pharmaceutically acceptable excipient.

[0036] In some embodiments of the present invention, the pharmaceutically acceptable excipients include at least one of a filler, a disintegrant, a diluent, a lubricant, a binder, a wetting agent, a flavoring agent, a suspending agent, a solvent, a sustained-release agent, an emulsifier, an absorption enhancer, a surfactant or a preservative.

[0037] In some embodiments of the present invention, the filler is selected from at least one of starch, sucrose, lactose, mannitol, sorbitol, xylitol, microcrystalline cellulose or glucose; the disintegrant is selected from at least one of corn starch, potato starch, microcrystalline cellulose, sodium carboxymethyl starch, cross-linked polyvinyl pyrrolidone, low-substituted hydroxypropyl cellulose, sodium carboxymethyl starch, carboxymethyl cellulose, cross-linked sodium carboxymethyl cellulose, calcium carboxymethyl cellulose and alginic acid; the diluent is selected from at least one of lactose, sucrose, mannitol, corn starch, potato starch, calcium phosphate, calcium citrate and crystalline cellulose; the lubricant is selected from at least one of stearic acid, polyethylene glycol, calcium carbonate, sodium bicarbonate, micropowder silica gel, talc, anhydrous silica gel and stearic acid at least one of magnesium; the binder is selected from at least one of cellulose derivatives, alginate, starch, water, dextrin, gelatin, hydroxypropyl cellulose, methyl cellulose or polyvinyl pyrrolidone; the wetting agent is selected from at least one of glycerol, Tween-80, oxyhydrogenated castor oil, sodium lauryl sulfate and lecithin; the flavoring agent is selected from at least one of aspartame, sucralose, flavor, stevioside, acesulfame potassium, citric acid and saccharin sodium; the suspending agent is selected from at least one of micro-powdered silica gel, beeswax, cellulose, sodium carboxymethyl cellulose and solid polyethylene glycol; the solvent is selected from at least one of water, ethanol, liquid polyethylene glycol, isopropanol, Tween-80, glycerol, propylene glycol and vegetable oil, wherein the vegetable oil is selected At least one of rapeseed oil, beeswax, soybean oil, castor oil, peanut oil, and blending oil; the sustained-release agent is selected from ethyl cellulose, cellulose acetate, polyethylene, polypropylene, polylactic acid, polyglycolic acid, polylactic acid-polyglycolic acid copolymer, polyethylene hydrogen, polycarbonate, epoxy resin, polyamide, acetal polymer, polyester, polyurethane, polyimide and polystyrene derivatives, cellulose acetate phthalate, hydroxypropyl methylcellulose phthalate, gelatin, peach gum, and polyvinyl pyrrolidone; the emulsifier is selected from anionic surfactants (such as sodium stearate, potassium stearate, sodium oleate, potassium oleate, calcium stearate, sodium lauryl sulfate, hexadecyl sulfated castor oil), zwitterionic surfactants At least one of the following: surfactants (such as lecithin and soybean lecithin), non-ionic surfactants (such as polysorbates, fatty acid sorbitol esters, poloxamers, glyceryl monostearate, glyceryl tristearate, sucrose stearate, polyoxyethylene fatty acid esters, polyoxyethylene fatty alcohol ethers), gum arabic, gelatin, tragacanth, oil-in-water (O / W) emulsifiers (such as magnesium hydroxide, aluminum hydroxide, silicon dioxide, bentonite), and water-in-oil (W / O) emulsifiers (calcium hydroxide, zinc hydroxide, magnesium stearate); the absorption promoter is selected from at least one of sodium octanoate and its derivatives, sodium caprate and its derivatives, alkyl glycosides, EDTA, chitosan and its derivatives, and polyamide-amine dendrimers (PAMAM);The surfactant is selected from at least one of sodium dodecylbenzene sulfonate, stearic acid, polyoxyethylene-polyoxypropylene (PEO-PPO) block polyether, fatty acid sorbitan and polysorbate; the preservative is selected from at least one of methyl paraben and propyl paraben. ;

[0038] In some embodiments of the present invention, the dosage form of the Chinese medicine composition includes any one of decoction, tablet, capsule, granule, pill, oral liquid, powder or paste.

[0039] In some embodiments of the present invention, the traditional Chinese medicine composition is a pill.

[0040] In some embodiments of the present invention, the Chinese medicine composition is a composition obtained by mixing the raw medicinal materials of each component after crushing; and / or an extract obtained by mixing the raw medicinal materials of each component and extracting, and / or an extract obtained by mixing the raw medicinal materials of each component after extracting separately. Optionally, the extract is further refined and purified. Among them, the extraction method includes decoction extraction, reflux extraction, immersion extraction, ultrasonic extraction, percolation extraction, microwave extraction, etc.: the refining and purification method includes water extraction and alcohol precipitation, alkali dissolution and acid precipitation and / or various column chromatography purification methods, such as macroporous resin column, silica gel column, gel column, reverse phase column, etc.

[0041] The second aspect of the present invention provides use of the traditional Chinese medicine composition provided in the first aspect in preparing a medicament for treating atrial fibrillation.

[0042] Treatment in the present invention includes delaying and stopping the progression of the disease, or eliminating the disease, and does not require 100% inhibition, elimination, or reversal.

[0043] In some embodiments of the present invention, the drug for treating atrial fibrillation comprises at least one of a1)-a3):

[0044] a1) Drugs that reduce the duration of the subject's P wave;

[0045] a2) drugs that reduce the incidence of atrial fibrillation in subjects;

[0046] a3) drugs that reduce the duration of atrial fibrillation in subjects;

[0047] Wherein the subject is a subject suffering from atrial fibrillation.

[0048] Example

[0049] This embodiment prepares a Chinese medicine composition, and the specific process is as follows:

[0050] Prescription 1: 500 parts of Ganoderma lucidum, 250 parts of pearls, 7 parts of aconite, 150 parts of ginseng, 150 parts of safflower, 25 parts of musk, 25 parts of bezoar, 25 parts of bear bile, 25 parts of toad venom, and 15 parts of borneol.

[0051] Prescription 2: 550 parts of Ganoderma lucidum, 250 parts of pearls, 12 parts of aconite, 200 parts of ginseng, 180 parts of safflower, 35 parts of musk, 35 parts of bezoar, 55 parts of bear bile, 45 parts of toad venom, and 15 parts of borneol.

[0052] Prescription 3: 550 parts of Ganoderma lucidum, 200 parts of pearls, 15 parts of aconite, 200 parts of ginseng, 180 parts of safflower, 25 parts of musk, 50 parts of bezoar, 12 parts of bear bile, 45 parts of toad venom, and 10 parts of borneol.

[0053] Process preparation:

[0054] All medicinal materials are powdered separately and then mixed; the coating pot is equipped with a built-in water spraying device, and the powder is sprinkled into the coating pot. First, a small amount of powder is added, and the water spraying is turned on for 2 minutes and the coating pot is rotated; the water spraying is stopped, and the coating pot is continued to be rolled, and water is sprayed and powdered repeatedly. The particles are firm and form solid and fine particles. Subsequently, a 1mm aperture pill mold is used for screening, and pills with a diameter of 1mm are collected, which are the finished products.

[0055] Pharmacological research

[0056] 1 Experimental methods

[0057] 1.1 Modeling

[0058] The animals used in the experiment were Sprague-Dawley rats.

[0059] Preparation of atrial fibrillation model: The atrial fibrillation model was prepared by tail vein injection of calcium chloride-acetylcholine (CaCl2-ACh). The model group and each treatment group were injected with CaCl2-ACh mixture by tail vein, and the normal control group was injected with the same volume of 0.9% sodium chloride solution by tail vein. Acetylcholine 66μg·mL -1 , calcium chloride 10mg·mL -1 , dissolved in 0.9% sodium chloride solution, mixed and then 1 mL·kg -1 ·d -1 , 250 mL / mouse, continuously injected through the tail vein for 14 days, and the normal control group (control group, 10 mice) was given the same dose of 0.9% sodium chloride solution.

[0060] 1.2 Grouping and Dosing

[0061] The appearance of f wave and disappearance of P wave in the electrocardiogram were taken as signs of successful modeling, and the rats with successful modeling were randomly divided into a model group (AF group, 10 rats), an original formula group (OHP group, 10 rats), a new formula group (NHP group, 10 rats), and an amiodarone group (Ver group, 10 rats). Amiodarone is a commercially available product. Rats in the control group and the model group were orally gavaged with an equal amount of normal saline. After modeling, the original formula group, the new formula group (Example 1), and the amiodarone group were respectively administered with the original formula, the new formula, and the positive drug amiodarone, and the administration was continued for 14 days. The oral gavage dosage of the original formula group and the new formula group was 12.2 mg·kg -1 ·d -1 The oral dose of amiodarone was 30.5 mg kg -1 ·d -1 The model group and the control group were gavaged with normal saline, 2 mL once a day, for 14 consecutive days.

[0062] 1.3 Detection Method

[0063] Electrocardiogram test: On the 14th day after the start of drug administration, all rats were weighed and anesthetized with chloral hydrate at a dose of 0.3 mL / 100 g. The rats were connected to a PowerLab 15T multi-conductivity physiological recorder, placed in a supine position on a wooden board, and the limbs were fixed with rubber bands. A metal needle was inserted into the subcutaneous part of the sterilized limbs, and the end of the lead was dipped in saline and clamped to the exposed end of the needle. The II lead electrocardiogram was measured and the dynamic observation was performed for 30 minutes.

[0064] 2. Experimental results

[0065] Electrocardiogram results such as Figure 1 As shown in the results, in this experiment, compared with the control group (control group), the incidence, duration, and P wave duration of atrial fibrillation in the model group (AF group) were significantly increased, and the difference was statistically significant (P<0.01). Compared with the AF group, the original formula group (OHP group) in the drug-treated group failed to improve the calcium chloride-acetylcholine-induced atrial fibrillation signs, while the positive drug amiodarone group (Ver group) and the new formula (NHP) significantly improved the atrial fibrillation-related signs (P<0.01), and the results were statistically significant.

[0066] It has been verified that the therapeutic effects of the Chinese medicine compositions of Prescription 2 and Prescription 3 are similar to that of Prescription 1.

[0067] The above embodiments are preferred implementation modes of the present invention, but the implementation modes of the present invention are not limited to the above embodiments. Any other changes, modifications, substitutions, combinations, and simplifications that do not deviate from the spirit and principles of the present invention should be equivalent replacement methods and are included in the protection scope of the present invention.

Claims

1. A Chinese medicine composition, wherein the raw medicinal materials of the Chinese medicine composition include, by weight: 380-550 parts of ganoderma lucidum, 150-250 parts of pearls, 5-20 parts of aconite root, 150-350 parts of ginseng, 100-200 parts of safflower, 10-50 parts of musk, 5-75 parts of bezoar, 10-80 parts of bear gall, 4-60 parts of toad venom, and 10-20 parts of borneol.

2. The Chinese medicine composition according to claim 1, characterized in that: The raw medicinal materials of the Chinese medicine composition include any one of A1)-A3): A1) 500 parts of ganoderma lucidum, 250 parts of pearls, 7 parts of aconite root, 150 parts of ginseng, 150 parts of safflower, 25 parts of musk, 25 parts of bezoar, 25 parts of bear gall, 25 parts of toad venom, and 15 parts of borneol; A2) 550 parts of ganoderma lucidum, 250 parts of pearls, 12 parts of aconite root, 200 parts of ginseng, 180 parts of safflower, 35 parts of musk, 35 parts of bezoar, 55 parts of bear gall, 45 parts of toad venom, and 15 parts of borneol; A3) 550 parts of ganoderma lucidum, 200 parts of pearls, 15 parts of aconite root, 200 parts of ginseng, 180 parts of safflower, 25 parts of musk, 50 parts of bezoars, 12 parts of bear gall, 45 parts of toad venom, and 10 parts of borneol.

3. The Chinese medicine composition according to claim 1, characterized in that The raw medicinal materials include any form of dry medicinal materials, fresh medicinal materials, raw medicinal materials, cooked medicinal materials, and processed medicinal materials.

4. The Chinese medicine composition according to claim 1, characterized in that: The raw medicinal materials include any one of natural medicinal materials and natural medicinal material equivalent substitutes.

5. The Chinese medicine composition according to claim 1, characterized in that: The traditional Chinese medicine composition also includes pharmaceutically acceptable excipients.

6. The Chinese medicine composition according to claim 5, characterized in that: The pharmaceutically acceptable excipients include at least one of a filler, a disintegrant, a diluent, a lubricant, a binder, a wetting agent, a flavoring agent, a suspending agent, a solvent, a sustained-release agent, an emulsifier, an absorption enhancer, a surfactant or a preservative.

7. The Chinese medicine composition according to claim 1, characterized in that: The Chinese medicine composition is a composition obtained by mixing the raw medicinal materials of each component after crushing; and / or an extract obtained by mixing the raw medicinal materials of each component and extracting, and / or an extract obtained by mixing the raw medicinal materials of each component after extracting separately.

8. The Chinese medicine composition according to claim 1, characterized in that: The dosage form of the Chinese medicine composition includes any one of decoction, tablet, capsule, granule, pill, oral liquid, powder or paste.

9. Use of the Chinese medicine composition according to any one of claims 1 to 8 in the preparation of a medicament for treating atrial fibrillation.

10. The use according to claim 9, wherein the drug for treating atrial fibrillation comprises at least one of a1) to a3): a1) Drugs that reduce the duration of the subject's P wave; a2) drugs that reduce the incidence of atrial fibrillation in subjects; a3) Medications that reduce the duration of atrial fibrillation in subjects.

Images